Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin for prevention of chronic graft-versus-host disease after hematopoietic progenitor cell transplantation
ISRCTN29899028Phase 3Completed
- Sponsor
- McMaster University
- Start
- Mar 2010
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by McMaster University. Primary endpoint: Freedom from chronic graft-versus-host disease at 12 months. Started Mar 2010; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ISRCTN29899028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29899028.